scholarly journals PIN30 - AN ECONOMIC MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

2018 ◽  
Vol 21 ◽  
pp. S225 ◽  
Author(s):  
J. Jacob ◽  
F. Bianic ◽  
L. Skinner ◽  
S. Carroll ◽  
H. Bricout ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Economic Model ◽  
Elderly Population ◽  
The Elderly ◽  
High Dose ◽  
England And Wales ◽  
Trivalent Influenza Vaccine ◽  
The Cost

scholarly journals Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

2021 ◽  
Vol 8 ◽  
pp. 105-113
Author(s):  
Filippo Rumi ◽  
Michele Basile ◽  
Americo Cicchetti
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Elderly Population ◽  
Impact Analysis ◽  
Budget Impact ◽  
Standard Dose ◽  
Public Health Problem ◽  
High Dose ◽  
Health Technologies ◽  
Quadrivalent Influenza Vaccine

Introduction. Influenza is a widespread acute respiratory disease and represents a serious Public Health problem, both from the NHS and society perspectives. The High Dose quadrivalent influenza vaccine (QIV HD) is a flu vaccine containing 4 times the antigens of a Standard Dose vaccine, resulting in demonstrated superior protection in the population aged 65 years and over. Methods. The analysis has been conducted from the perspective of the NHS. The CEA focuses on the comparison between QIV HD and the QIV SD vaccine. The BIM aims to estimate the potential economic impact for the National Health Service (NHS) resulting from the use of QIV HD in clinical practice in subjects aged 65 or over, when considering its introduction in combination with currently used vaccines, QIV SD and adjuvanted TIV. Results. In a scenario which considers hospitalizations possibly related to influenza, so including cardio-respiratory events, a dominant cost-effectiveness profile emerges in the comparison with QIV SD. In terms of budget impact, overall savings obtained by comparing the two scenarios regarding hospitalizations are equal to 92,766,429 € over the three years’ time horizon considered in the analysis. Conclusions. Nowadays, also considering the state of emergency due to the spread of the SARS-CoV-2 virus, it is crucial to implement innovative health technologies that improve the efficiency and sustainability of the health system. Also, it is essential to protect the elderly population, helping to avoid overload and healthcare systems disruption due to the many COVID-19 hospitalizations.

Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China

Vaccine ◽  
2020 ◽  
Vol 38 (5) ◽  
pp. 1057-1064 ◽  
Author(s):  
Minghuan Jiang ◽  
Pengchao Li ◽  
Weihua Wang ◽  
Mingyue Zhao ◽  
Naveel Atif ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Elderly Population ◽  
Trivalent Influenza Vaccine

scholarly journals 1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S444-S444
Author(s):  
Van Nguyen ◽  
Carla Vizzotti ◽  
Analia Uruena ◽  
Norberto Giglio ◽  
Maria Cecilia Magneres ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
Trivalent Influenza Vaccine ◽  
The Cost

scholarly journals Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors

Vaccine ◽  
2015 ◽  
Vol 33 (5) ◽  
pp. 734-741 ◽  
Author(s):  
Ayman Chit ◽  
Julie Roiz ◽  
Benjamin Briquet ◽  
David P. Greenberg
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccine ◽  
High Dose ◽  
Expected Cost ◽  
Trivalent Influenza Vaccine

scholarly journals Unruptured aneurysms in the elderly: perioperative outcomes and cost analysis of endovascular coiling and surgical clipping

2018 ◽  
Vol 44 (5) ◽  
pp. E4 ◽  
Author(s):  
Nicole A. Silva ◽  
Belinda Shao ◽  
Michael J. Sylvester ◽  
Jean Anderson Eloy ◽  
Chirag D. Gandhi
Keyword(s):  
Cost Effectiveness ◽  
Elderly Patients ◽  
Hospital Mortality ◽  
Conservative Management ◽  
Elderly Population ◽  
The Elderly ◽  
Hospital Charges ◽  
Perioperative Outcomes ◽  
Elderly Individuals ◽  
The Cost

OBJECTIVEObservation and neurosurgical intervention for unruptured intracranial aneurysms (UIAs) in the elderly population is rapidly increasing. Cerebral aneurysm coiling (CACo) is favored over cerebral aneurysm clipping (CAC) in elderly patients, yet some elderly individuals still undergo CAC. The cost-effectiveness of treating UIAs requires further exploration. Understanding the effect of intervention on hospital charges and length of stay (LOS) as well as perioperative mortality and complications can further shed light on its economic impact. The purpose of this study was to analyze the cost and perioperative outcomes of UIAs in elderly patients (≥ 65 years of age) after CACo or CAC intervention.METHODSRetrospective cohorts of CACo and CAC admissions were extracted from National (Nationwide) Inpatient Sample data obtained between 2002 and 2013, forming parallel intervention groups to compare the following outcomes between elderly and nonelderly patients: average LOS and mean hospital admission costs, in-hospital mortality, and complications. Covariates included sex, race or ethnicity, and comorbidities.RESULTSElderly patients undergoing CAC experienced an average LOS of 8.0 days, whereas elderly patients undergoing CACo stayed an average of 3.2 days. The mean hospital charges incurred during admission totaled $95,960 in the elderly patients who underwent CAC versus $87,960 in the ones who underwent CACo. Elderly patients in whom CAC was performed had a 2.2% rate of in-hospital mortality, with a 2.6 greater adjusted odds of in-hospital mortality than nonelderly patients treated with CAC. In contrast, elderly patients who underwent CACo had a 1.36 greater adjusted odds of in-hospital mortality than their nonelderly counterparts. Compared to nonelderly patients receiving both interventions, elderly individuals had a significantly higher prevalence of various comorbidities and incidence of complications. Elderly patients who received CAC experienced a 10.3% incidence rate of perioperative stroke, whereas their CACo counterparts experienced this complication at a rate of 3.5%. Elderly patients treated with CAC had greater odds of perioperative acute renal failure, whereas their CACo counterparts had greater odds of perioperative deep venous thrombosis and pulmonary embolism.CONCLUSIONSIntervention with CAC and CACo in the elderly is resource intensive and is associated with higher risk than in the nonelderly. Those deciding between intervention and conservative management should consider these risks and costs, especially the 2.2% postoperative mortality rate associated with CAC in the elderly population. Further comparative cost-effectiveness research is needed to weigh these costs and outcomes against those of conservative management.

scholarly journals High-dose trivalent influenza vaccine: safety and immunogenicity

2020 ◽  
Author(s):  
Raúl Ortiz de Lejarazu ◽  
◽  
Federico Martinón Torres ◽  
Ángel Gil de Miguel ◽  
Javier Díez Domingo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Influenza Vaccine ◽  
Randomized Clinical Trials ◽  
Standard Dose ◽  
Meta Analysis ◽  
Influenza Virus Infection ◽  
The Elderly ◽  
The United States ◽  
High Dose ◽  
Trivalent Influenza Vaccine

Adults aged 65 years or older suffer the most severe health effects of seasonal flu. Although the influenza vaccine is effective in preventing influenza virus infection and its complications, it is not as effective in the elderly due to age-associated immunosenescence phenomenon. Since 2009, a high-dose trivalent influenza vaccine has been approved in the United States for the immunization of people ≥ 65 years with an antigen concentration four times higher than the standard vaccine. Multiple clinical trials carried out over different seasons, and using different methodologies, have shown that the high-dose trivalent influenza vaccine is not only more effective, but it also has a similar safety profile and is more immunogenic than the standard dose vaccine in the prevention of flu and its complications in the elderly. This document reviews the current scientific evidence on the safety and immunogenicity of high-dose influenza vaccine in people aged 65 years and over, and includes information from randomized clinical trials, observational studies with data from real clinical practice, and systematic reviews, and meta-analysis.

Sign in / Sign up

Export Citation Format

Share Document